CompaniesOBI Pharma
OBI Pharma logo

OBI Pharma

active
Taipei, Taiwan
Founded 2002
Website
About

Biologics

Areas of Focus

Categories

Biologics & BiopharmaceuticalTaiwan
Team (10)
Christa Maurer
Senior Director, Quality Assurance (OBI Pharma USA, Inc.)
OBI Pharma
team_member
Colin Kao
Chief Operating Officer
OBI Pharma
executive
David Huang, PH.D.
Senior Director, ADC Enabling Technologies
OBI Pharma
team_member
Dong Xu, Ph. D.
Chief Medical Officer (OBI Pharma USA, Inc.)
OBI Pharma
executive
Heidi Wang, Ph. D.
Director and Chief Executive Officer
OBI Pharma
executive
Kevin P Poulos
Chief Business Officer (OBI Pharma USA, Inc.)
OBI Pharma
team_member
View all 10 team members →
Clinical Trials (10)
View all

Total Trials

10

As Lead Sponsor

9

As Collaborator

1

Total Enrollment

1,513

By Phase

PHASE1/PHASE2: 5PHASE2: 3PHASE3: 1PHASE1: 1

By Status

TERMINATED: 3RECRUITING: 2ACTIVE_NOT_RECRUITING: 2COMPLETED: 2UNKNOWN: 1
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
NCT01516307
NCT02132988
NCT02310464
NCT03573544
NCT03592264
NCT03562637
NCT04084366
NCT05442060
NCT07124117
Hover over trial bars to see details

Recent Trials

NCT07124117Lead Sponsor
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
PHASE1/PHASE2Recruiting
111 participants
Started: Aug 4, 2025 · Completed: Feb 8, 2029
NCT06480240Lead Sponsor
A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
PHASE1/PHASE2Active, not recruiting
117 participants
Started: Jun 12, 2024 · Completed: Jun 30, 2027
NCT05442060Lead Sponsor
To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
PHASE2Recruiting
60 participants
Started: Jul 27, 2022 · Completed: May 31, 2026
NCT04084366Lead Sponsor
Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors
PHASE1/PHASE2Terminated
44 participants
Started: Nov 25, 2019 · Completed: Oct 27, 2023
NCT03562637Lead Sponsor
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
PHASE3Active, not recruiting
575 participants
Started: Dec 5, 2018 · Completed: Dec 30, 2027
View all 10 trials →
Locations (1)
Headquarters
Taipei, Taiwan
Map

Loading map...